Dextromethorphan/ bupropion · Auvelity
Small molecule
Evidence outlook
Approved: Major Depressive Disorder, Alzheimer's Disease Agitation
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Company guidance: topline data expected 2H 2027 (NCT07766655; Axsome Therapeutics, 2 Nov 2026). “Evaluating AXS-05 as a treatment for smoking cessation Key eligibility criteria 18-65 years of age Primary endpoint Change from baseline in smoking abstinence SUMMIT Phase 3 trial 26 AXS-05 Bupropion Placebo 1:1:1 R Screening Double-blind phase (12 weeks) Follow-up Baseline Topline results anticipated 2H 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STRIDE-1 NCT02741791 · Treatment Resistant Major Depressive Disorder This was a randomized, double-blind, active-controlled trial with 312 participants, using change in the clinical MADRS depression score as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT02741791 | 3 | Montgomery-Åsberg Depression Rating Scale (MADRS) total score (MADRS change from Baseline to End of Study (6 weeks)) 2020-03-20 | Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 | Partial signal | link ↗ |
View 2 more trials
GEMINI NCT04019704 · Major Depressive Disorder This was a randomized, quadruple-blind, placebo-controlled trial in 327 people, more than the 300 the protocol planned, and AXS-05 met its primary goal of a larger drop in MADRS depression score than placebo at week 6 (p=0.002). Registry: NCT04019704 | 3 | Change in MADRS Total Score From Baseline to Week 6 (6 weeks) 2019-11-26 | Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862) | Reliable signal | link ↗ |
ASCEND NCT03595579 · Major Depressive Disorder The trial was randomized and quadruple-blind, used bupropion as an active comparator, and evaluated the clinical symptom measure MADRS; 97 participants were randomized, with 43 AXS-05 and 37 bupropion participants in the modified intent-to-treat analysis. The primary endpoint was met, but the available record does not report a power calculation, so the evidence is graded moderate rather than strong. Registry: NCT03595579 | 2 | MADRS Score - Overall Change From Baseline (Assessed at week 1, 2, 3, 4, 5 and 6 (averaged over the entire 6-week treatment period)) 2019-01-07 | MADRS Score - Overall Change From Baseline (Assessed at week 1, 2, 3, 4, 5 and 6 (averaged over the entire 6-week treatment period)): AXS-05 13.7 score on a scale (Standard Error 0.63) vs Bupropion 8.8 score on a scale (Standard Error 0.68) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Dopamine/norepinephrine transporter drugs
naltrexone/bupropion, Solriamfetol. Compare all 3 Dopamine/norepinephrine transporter drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Alzheimer's Disease Agitation: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dextromethorphan / Bupropion (Auvelity): this drug | Approved | Small molecule | Dopamine/norepinephrine transporter, sigma-1/NMDA | Reliable signal | NCT05557409: Change in CMAI total score, baseline to Week 5 (ADVANCE-2): -13.8 points AXS-05 vs -12.6 points placebo; did not reach statistical significance missed NCT03226522: Change in CMAI Total Score (5 weeks): AXS-05 -15.4 score on a scale (Standard Error 1.25) vs Bupropion -10 score on a scale (Standard Error 3.02) vs Placebo -11.5 score on a scale (Standard Error 1.1) | |
| Naltrexone / Bupropion (Contrave) | Approved(overall) | Small molecule | Opioid receptor / dopamine (combination), Dopamine/norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3(overall; approved for another use) | Small molecule | Alpha-2 adrenergic receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| AVP-786 | Discontinued | Combination | sigma-1/NMDA | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Auvelity (Dextromethorphan/bupropion) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Company guidance: topline data expected 2H 2027 (Axsome Therapeutics, 2 Nov 2026). “Evaluating AXS-05 as a treatment for smoking cessation Key eligibility criteria 18-65 years of age Primary endpoint Change from baseline in smoking abstinence SUMMIT Phase 3 trial 26 AXS-05 Bupropion Placebo 1:1:1 R Screening Double-blind phase (12 weeks) Follow-up Baseline Topline results anticipated 2H 2027” Source ↗
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent